drugset

drugset / Trial / NCT00185562

A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis

NCT00185562 ↗

Phase 2 Completed 12 enrolled Stanford University

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A 12 week trial of Adalimumab in subjects with active erosive inflammatory OA who have ahd an inadequate response to NSAID therapy

Timeline

Start: 2005-06
Primary completion: —
Completion: 2006-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	—	—

Indications